Zumilokibart

组米洛奇拜单抗

Report date: 2026/04/17 20:02:02

Base Information

Drug NameZumilokibart
Drug Alias NameAPG777APG-777PR004PR-004APG 777
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-13 inhibitors
TargetsInterleukin-13
Therapy Area/IndicationsDermatitis, AtopicAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[11
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesApogee Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesApogee Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A